IPSEN (OTCMKTS:IPSEY) Sets New 52-Week High – Here’s What Happened

IPSEN (OTCMKTS:IPSEY)’s share price reached a new 52-week high on Wednesday . The company traded as high as $47.81 and last traded at $47.81, with a volume of 158 shares traded. The stock had previously closed at $44.97.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. UBS Group cut shares of IPSEN from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 8th. BNP Paribas Exane cut IPSEN to an “underperform” rating in a research report on Wednesday, November 26th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a research report on Tuesday, February 17th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold”.

IPSEN Trading Up 3.6%

The business’s fifty day moving average is $39.24 and its 200 day moving average is $36.26.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).